quarta-feira, julho 05, 2006
Tibotec desenvolve IP contra Hep C
Vertex Pharmaceuticals and Janssen Pharmaceutica, a Johnson & Johnson Company, Form Collaboration to Develop and Commercialize VX-950 for Treatment of Hepatitis C
Friday June 30, 8:00 am ET
- Vertex Retains all North American Rights -
- Janssen Obtains Exclusive Rights in Europe and Other Regions -
- Vertex to Receive $165 Million Upfront; Tiered Royalty Averaging mid-20 Percent Range Based on Successful Commercialization -
NEW BRUNSWICK, N.J. and CAMBRIDGE, Mass., June 30 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX - News) and Janssen Pharmaceutica, N.V., a Johnson & Johnson (NYSE: JNJ - News) company, announced today that they will collaborate to develop and commercialize Vertex's investigational hepatitis C virus (HCV) protease inhibitor, VX-950.
Under the agreement, Janssen will have exclusive rights in Europe, South America, the Middle East, Africa and Australia, and Vertex will retain exclusive commercial rights to VX-950 in North America. Tibotec Pharmaceuticals, Ltd., another Johnson & Johnson company, will lead the development and commercialization of VX-950 for Janssen.